PFE · 8-K · 20260804PR000094

Competition and Market Share

PFIZER INC · 2026-08-04 · Importance 17 · Surprise 24 · In source text

Eliquis continued to benefit from higher U.S. net pricing, but generic entry and price erosion reduced performance in certain international markets. Vyndaqel’s U.S. growth was partly offset by net price erosion resulting from new payer contracts. Padcev gained market share in first-line locally advanced or metastatic urothelial cancer, while its reported growth was partly offset by the prior-year impact of a transition to a U.S. wholesaler distribution model. Pfizer also expects approximately $1.1 billion of 2026 revenue pressure from recent and expected generic and biosimilar competition.

Key facts

• Pfizer expects an anticipated unfavorable revenue impact of approximately $1.1 billion in 2026 due to recent and expected generic and biosimilar competition source

Impact estimates